[go: up one dir, main page]

PE20242300A1 - Compuestos, procedimiento de produccion de compuestos, extracto enriquecido, fracciones activas de extractos enriquecidos, procedimiento de produccion de extractos enriquecidos, metodo para seleccionar biomasa vegetal para produccion, composicion y uso de extractos enriquecidos para el tratamiento de trastornos inmunologicos - Google Patents

Compuestos, procedimiento de produccion de compuestos, extracto enriquecido, fracciones activas de extractos enriquecidos, procedimiento de produccion de extractos enriquecidos, metodo para seleccionar biomasa vegetal para produccion, composicion y uso de extractos enriquecidos para el tratamiento de trastornos inmunologicos

Info

Publication number
PE20242300A1
PE20242300A1 PE2024002048A PE2024002048A PE20242300A1 PE 20242300 A1 PE20242300 A1 PE 20242300A1 PE 2024002048 A PE2024002048 A PE 2024002048A PE 2024002048 A PE2024002048 A PE 2024002048A PE 20242300 A1 PE20242300 A1 PE 20242300A1
Authority
PE
Peru
Prior art keywords
production
enriched
procedure
extracts
enriched extracts
Prior art date
Application number
PE2024002048A
Other languages
English (en)
Inventor
Cristiano Ruch Werneck Guimarães
Carlos Eduardo Vitor
Lisandra Ravanelli Pessa
Romulo Dragani Reis
Alessandra Mascarello
Fernando Henrique De Souza Gama
Original Assignee
Ache Laboratorios Farmaceuticos Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ache Laboratorios Farmaceuticos Sa filed Critical Ache Laboratorios Farmaceuticos Sa
Publication of PE20242300A1 publication Critical patent/PE20242300A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D311/00Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/94Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/74Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C07C69/757Esters of carboxylic acids having an esterified carboxyl group bound to a carbon atom of a ring other than a six-membered aromatic ring having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/85Verbenaceae (Verbena family)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/42Separation; Purification; Stabilisation; Use of additives
    • C07C51/47Separation; Purification; Stabilisation; Use of additives by solid-liquid treatment; by chemisorption
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/42Unsaturated compounds containing hydroxy or O-metal groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/76Unsaturated compounds containing keto groups
    • C07C59/90Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40Unsaturated compounds
    • C07C59/76Unsaturated compounds containing keto groups
    • C07C59/92Unsaturated compounds containing keto groups containing —CHO groups
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/10Systems containing only non-condensed rings with a five-membered ring the ring being unsaturated
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Medical Informatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

Se describen compuestos aislados y un procedimiento de produccion de compuestos y extractos con actividad inmunosupresora, de plantas del genero Stachytarpheta. Tambien describe composiciones y su usa para el tratamiento de trastornos inmunologicos. En particular, se refiere a compuestos que comprenden la formula general (I), (II) y (III), en donde R es H, OH, OGIyc (glicosido); R1, R1', R1'' corresponden a H, OH; R2 es H, COOH, COOCH3, CH3, CHO; R3 es H, OH, CH3; R4, R4' corresponden a H, OH, CH2OH, CH3; R5, R5' corresponden a H, CH3, COOCH3, CHO, CH2OH; R6 es CHO, COOH, COOCH3; R7 es H, CH3; R8, R8', R8'' corresponden a CHO, CH3, CH2OH, COOH y los enlaces discontinuos representan enlaces simples (C-C) o dobles (C=C) entre carbonos (hasta dos dobles enlaces por estructura).
PE2024002048A 2017-02-17 2018-02-19 Compuestos, procedimiento de produccion de compuestos, extracto enriquecido, fracciones activas de extractos enriquecidos, procedimiento de produccion de extractos enriquecidos, metodo para seleccionar biomasa vegetal para produccion, composicion y uso de extractos enriquecidos para el tratamiento de trastornos inmunologicos PE20242300A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
BR102017003318-0A BR102017003318A2 (pt) 2017-02-17 2017-02-17 compostos, processo de produção de compostos, extrato enriquecido, frações ativas de extrato enriquecido, processo de produção de extrato enriquecido, método de seleção de biomassa vegetal para produção de extrato enriquecido, composição e uso para tratamento de desordens imunológicas
PCT/BR2018/050037 WO2018148816A2 (en) 2017-02-17 2018-02-19 Compounds, process of production of compounds, enriched extract, enriched extract active fractions, enriched extract process of production, method for selecting vegetal biomass for enriched extract production, composition and use for treatment of immunological disorders

Publications (1)

Publication Number Publication Date
PE20242300A1 true PE20242300A1 (es) 2024-12-11

Family

ID=61282932

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2019001711A PE20200449A1 (es) 2017-02-17 2018-02-19 Compuestos, procedimiento de produccion de compuestos, extracto enriquecido, fracciones activas de extractos enriquecidos, procedimiento de produccion de extractos enriquecidos, metodo para seleccionar biomasa vegetal para produccion, composicion y uso de extractos enriquecidos para el tratamiento de trastornos inmunologicos
PE2024002048A PE20242300A1 (es) 2017-02-17 2018-02-19 Compuestos, procedimiento de produccion de compuestos, extracto enriquecido, fracciones activas de extractos enriquecidos, procedimiento de produccion de extractos enriquecidos, metodo para seleccionar biomasa vegetal para produccion, composicion y uso de extractos enriquecidos para el tratamiento de trastornos inmunologicos

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2019001711A PE20200449A1 (es) 2017-02-17 2018-02-19 Compuestos, procedimiento de produccion de compuestos, extracto enriquecido, fracciones activas de extractos enriquecidos, procedimiento de produccion de extractos enriquecidos, metodo para seleccionar biomasa vegetal para produccion, composicion y uso de extractos enriquecidos para el tratamiento de trastornos inmunologicos

Country Status (29)

Country Link
US (1) US20200231561A1 (es)
EP (2) EP3583103B1 (es)
JP (2) JP7349362B2 (es)
KR (2) KR102882868B1 (es)
CN (1) CN110475768B (es)
AU (2) AU2018221956B2 (es)
BR (2) BR102017003318A2 (es)
CA (2) CA3052713A1 (es)
CL (1) CL2019002309A1 (es)
CO (1) CO2019008891A2 (es)
CY (1) CY1125187T1 (es)
DK (1) DK3583103T3 (es)
EC (1) ECSP19058322A (es)
ES (1) ES2909387T3 (es)
HR (1) HRP20220377T1 (es)
IL (2) IL268732B2 (es)
LT (1) LT3583103T (es)
MX (2) MX2019009655A (es)
NZ (1) NZ756074A (es)
PE (2) PE20200449A1 (es)
PL (1) PL3583103T3 (es)
PT (1) PT3583103T (es)
RS (1) RS63162B1 (es)
SA (1) SA519402443B1 (es)
SG (1) SG11201907375VA (es)
SI (1) SI3583103T1 (es)
SM (1) SMT202200121T1 (es)
WO (1) WO2018148816A2 (es)
ZA (2) ZA201906106B (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115304652A (zh) * 2022-07-25 2022-11-08 福建华闽晟业生物科技有限公司 一种利用巨菌草制备野芝麻新甙的方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3703543A (en) * 1969-11-05 1972-11-21 American Home Prod Hydroxamic acids of alicyclic amino acids
ATE715T1 (de) * 1978-06-03 1982-03-15 Institut De Recherches Chimiques Et Biologiques Appliquees (I.R.C.E.B.A.) Societe A Responsabilite Limitee Dite: Arzneimittel mit einem gehalt an einem cyclopentylaldehyd-derivat.
DE3030477C2 (de) * 1980-08-12 1986-10-16 Dr. Willmar Schwabe GmbH & Co, 7500 Karlsruhe Iridoid-Derivate, Verfahren zu ihrer Herstellung und deren Verwendung
JPH0366682A (ja) * 1989-08-04 1991-03-22 Tsumura & Co 新規イリドイド誘導体
US5272172A (en) * 1990-10-09 1993-12-21 Tsumura & Co. Iridoid derivatives and the use thereof as a drug
DE19644422C2 (de) * 1996-10-25 2000-06-15 Stefan Schulz Verwendung von Terpenen zur Behandlung von Autoimmunkrankheiten und bei Transplantat-Abstoßungsreaktionen
EP1145709A1 (de) * 2000-04-14 2001-10-17 Laboratoires Serobiologiques Verwendung von Naturstoffen zur Herstellung von kosmetischen Zubereitungen
AU2003224361B2 (en) * 2002-05-10 2008-01-31 Council Of Scientific And Industrial Research Hepatoprotective activity of 2'-p-Hydroxybenzoylmussaenosidic acid
EP1371372A1 (de) * 2002-06-08 2003-12-17 Cognis Iberia, S.L. Verwendung von Wirkstoffgemischen enthaltend Tocopherole und Extrakte des Harpagophytum procumbens zur Herstellung eines Medikamentes gegen rheumatische Arthritis
JP2008024670A (ja) * 2006-07-24 2008-02-07 Daiwa Kagaku Kogyo Kk 害虫駆除剤
BRPI0719505A2 (pt) * 2006-12-21 2013-12-10 Du Pont "Processos de preparação de óleo de erva dos gatos hidrogenado"
BRPI0700767B8 (pt) * 2007-02-15 2021-05-25 Ache Laboratorios Farmaceuticos Sa composição farmacêutica, produto farmaceutico, processo para obtenção de compostos farmaceuticos e uso de tais compostos para o tratamento do vitiligo
WO2013032308A2 (ko) * 2011-09-02 2013-03-07 동국대학교 산학협력단 라카아제를 이용한 새로운 효소형 시간-온도 이력지시계
CN103120699B (zh) * 2011-11-18 2017-04-19 天津市国际生物医药联合研究院 环烯醚萜类化合物在制备抗sars的药物中的应用
CN103690551A (zh) * 2013-07-18 2014-04-02 江苏大学 猪殃殃中环烯醚萜苷提取物及其提取方法和医药用途
DE102015102020A1 (de) * 2015-02-12 2016-08-18 Renate Wilmanowicz Immunologisch aktives Phyto-Gemisch und seine Anwendung bei der Prävention und in einem Verfahren zur Behandlung von Effloreszenzen

Also Published As

Publication number Publication date
KR20250145126A (ko) 2025-10-13
PT3583103T (pt) 2022-03-25
SMT202200121T1 (it) 2022-07-21
KR102882868B1 (ko) 2025-11-07
EP3583103B1 (en) 2022-01-12
EP4001270A1 (en) 2022-05-25
ES2909387T3 (es) 2022-05-06
CO2019008891A2 (es) 2020-01-17
ECSP19058322A (es) 2019-10-31
WO2018148816A2 (en) 2018-08-23
JP7685540B2 (ja) 2025-05-29
SG11201907375VA (en) 2019-09-27
CN110475768B (zh) 2023-12-01
CA3259255A1 (en) 2025-04-04
SA519402443B1 (ar) 2023-02-08
PE20200449A1 (es) 2020-02-28
MX2019009655A (es) 2020-07-24
AU2022201835B2 (en) 2024-05-30
JP2020507607A (ja) 2020-03-12
LT3583103T (lt) 2022-04-25
SI3583103T1 (sl) 2022-07-29
WO2018148816A4 (en) 2019-01-03
AU2022201835A1 (en) 2022-04-07
RS63162B1 (sr) 2022-05-31
AU2018221956A1 (en) 2019-08-29
HRP20220377T1 (hr) 2022-07-08
IL268732A (en) 2019-10-31
MX2022012282A (es) 2022-10-27
RU2019129095A (ru) 2021-03-17
NZ756074A (en) 2025-10-31
IL268732B2 (en) 2024-12-01
RU2019129095A3 (es) 2021-10-27
CA3052713A1 (en) 2018-08-23
JP7349362B2 (ja) 2023-09-22
ZA201906106B (en) 2020-08-26
KR20190121790A (ko) 2019-10-28
IL313974A (en) 2024-08-01
BR102017003318A2 (pt) 2018-10-30
BR112019017128A2 (pt) 2020-04-14
DK3583103T3 (da) 2022-03-14
JP2023061959A (ja) 2023-05-02
IL268732B1 (en) 2024-08-01
ZA202501840B (en) 2025-10-29
WO2018148816A3 (en) 2018-10-18
AU2018221956B2 (en) 2022-03-24
EP3583103A2 (en) 2019-12-25
US20200231561A1 (en) 2020-07-23
CL2019002309A1 (es) 2020-05-29
PL3583103T3 (pl) 2022-08-01
CN110475768A (zh) 2019-11-19
CY1125187T1 (el) 2023-06-09

Similar Documents

Publication Publication Date Title
ECSP22050936A (es) Compuestos tric?clicos sustituidos
CL2020000632A1 (es) Composición y método para el tratamiento del autismo.
DOP2018000257A (es) Piridinas sustituidas con heteroarilo y métodos de uso
CR20190063A (es) 3-metil pirazinas 2,5-disustituídas y 3-metil pirazinas 2,5,6-trisustituídas como inhibidores alostéricos de shp2
MX2019013561A (es) Compuestos de pirrolopiridina-anilina para el tratamiento de trastornos dermicos.
CL2009000429A1 (es) Compuestos derivados de carbamoil-heterociclos fusionados, en especial pirrolo[3,2-c]piridin-2-carboxamidas, inhibidores de smo; composicion farmaceutica que comprende dichos compuestos; y uso en la profilaxis o tratamiento del cancer.
CL2020002089A1 (es) Prevenir o reducir el crecimiento de las plantas por biocementación.
CO2019007409A2 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos
CL2007001711A1 (es) Compuestos derivados de pirazolopiridina sustituida;composicion farmaceutica que los comprende;metodo de preparacion de los compuestos ,compuestos intermediarios;y su uso en el tratamiento de enfermedades,tales como tumores,artritis reumatoide,enfermedades del crecimiento vascular desregulado, entre otras.
CL2017000293A1 (es) Compuestos derivados de benzofurano sustituido en posición 6 por un radical que contiene boro; composición farmacéutica que los comprende; uso en el tratamiento de la hepatitis c (divisional del cl 393-2014)
AR115081A1 (es) Aislados de microbacterias y sus usos
MX2022007671A (es) Compuestos antihelminticos que comprenden una estructura de azaindoles.
GT201700126A (es) Ácidos piridil-cicloalquil-carboxílicos sustituidos composiciones que los contienen y usos de los mismos
AR128109A1 (es) Spiros y análogos relacionados para inhibir yap / taz-tead
MX2024007929A (es) Tetrahidropirazolopirimidinas y analogos relacionados para la inhibicion de yap/taz-tead.
CO2024015524A2 (es) Compuestos aromáticos que contienen boro y análogos de insulina relacionados
CL2025000161A1 (es) Compuestos cíclicos y métodos de utilización de estos.
CL2024001635A1 (es) Compuestos de diazaspiro sustituidos con carbonilo y su uso
SA522432999B1 (ar) C-17 مركبات تراي تريبينويد تخليقية ذات مجموعات استبدال اساسها نيتروجين عند وطرق استخدامها
PE20242300A1 (es) Compuestos, procedimiento de produccion de compuestos, extracto enriquecido, fracciones activas de extractos enriquecidos, procedimiento de produccion de extractos enriquecidos, metodo para seleccionar biomasa vegetal para produccion, composicion y uso de extractos enriquecidos para el tratamiento de trastornos inmunologicos
MX2014000344A (es) Antagonistas de trpv1 que incluyen sustituyente dihidroxi y sus usos.
CL2021003384A1 (es) Composición y método para mejorar el crecimiento de las plantas
CL2008003154A1 (es) Proceso de obtencion de un extracto estandarizado de aleuterites moluccana; extracto estandarizado de aleurites moluccana; composicion farmaceutica que comprende el extracto; uso del extracto para tratar condiciones de dolor.
MX2014010926A (es) Composicion herbaria para el tratamiento de transtornos metabolicos.
AR110750A1 (es) Método para mejorar la salud de las plantas y el desarrollo de las raíces